Central Pharmaceuticals Ltd. (DSE:CENTRALPHL)

Central Pharmaceuticals Income Statement

Financials in millions BDT. Fiscal year is July - June.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020
Revenue	29.6	29.33	26	148.15	140.09
Revenue Growth (YoY)	0.93%	12.81%	-82.45%	5.75%	-54.44%
Cost of Revenue	50.21	58.36	63.58	118.89	629.42
Gross Profit	-20.61	-29.03	-37.58	29.27	-489.33
Selling, General & Admin	16.65	18.83	15.77	22.45	610.55
Other Operating Expenses	0.44	-	-	-	-
Operating Expenses	17.09	18.83	15.77	22.45	610.55
Operating Income	-37.7	-47.86	-53.35	6.82	-1,100
Interest Expense	-	-	-17.36	-21.36	-9.95
Interest & Investment Income	0.01	0	0	0.01	0.01
Other Non Operating Income (Expenses)	-0.01	-0.01	-0.11	-0.09	-0.03
EBT Excluding Unusual Items	-37.71	-47.87	-70.82	-14.63	-1,110
Asset Writedown	-10.59	-	-	-	-
Pretax Income	-48.3	-47.87	-70.82	-14.63	-1,110
Income Tax Expense	-5.88	-3.91	-2.57	-6.16	-2.85
Net Income	-42.42	-43.96	-68.25	-8.47	-1,107
Net Income to Common	-42.42	-43.96	-68.25	-8.47	-1,107
Shares Outstanding (Basic)	120	120	120	120	120
Shares Outstanding (Diluted)	120	120	120	120	120
EPS (Basic)	-0.35	-0.37	-0.57	-0.07	-9.24
EPS (Diluted)	-0.35	-0.37	-0.57	-0.07	-9.24
Free Cash Flow	2.97	-0.33	-1.12	-4.78	-0.41
Free Cash Flow Per Share	0.03	-0.00	-0.01	-0.04	-0.00
Gross Margin	-69.62%	-98.99%	-144.57%	19.75%	-
Operating Margin	-127.37%	-163.18%	-205.21%	4.60%	-785.11%
Profit Margin	-143.31%	-149.88%	-262.51%	-5.72%	-790.20%
Free Cash Flow Margin	10.02%	-1.11%	-4.31%	-3.22%	-0.29%
EBITDA	-13.66	-21.11	-23.59	39.71	-1,064
EBITDA Margin	-46.15%	-71.98%	-90.75%	26.80%	-
D&A For EBITDA	24.04	26.75	29.76	32.89	36.28
EBIT	-37.7	-47.86	-53.35	6.82	-1,100
EBIT Margin	-127.37%	-163.18%	-205.21%	4.60%	-

Updated Dec 24, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.